Evidence map›Paper›PMID 31059311›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.

Emil Christensen, Karin Birkenkamp-Demtröder, Himanshu Sethi, Svetlana Shchegrova, Raheleh Salari, Iver Nordentoft, Hsin-Ta Wu, Michael Knudsen, Philippe Lamy, Sia Viborg Lindskrog and 24 more

3 registry-linked trialsOpen access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 289 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
289citing papers in PubMed, 10 pooled it
48.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05736523 active not recruitingnot on this mapstarted 2020, after this paper: background citation

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

TypeobservationalSponsorUniversity of UtahRan2020 to 2025Enrolled28ConditionsMelanoma
NCT06167460 recruitingnot on this mapstarted 2023, after this paper: background citation

Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to Tyrosine Kinase Inhibitors in Patients With Advanced Non-small Cell Lung Cancer

TypeobservationalSponsorGene SolutionsRan2023 to 2025Enrolled50ConditionsNon Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
NCT06893133 recruitingnot on this mapstarted 2025, after this paper: background citation

Personalized ctDNA-MRD in Recurrence Monitoring for Gastric Cancer Patients Undergoing Perioperative Treatment Combined With Curative Surgical Resection

TypeobservationalSponsorPeking UniversityRan2025 to 2027Enrolled110ConditionsGastric Cancer
3 · Its place in the literature

Who cites it

289 citing papers in PubMed, 10 syntheses or guidelines pooled it, 526 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  13. Trial
  14. Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  15. Trial
  16. Trial
  17. Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT.Health technology assessment (Winchester, England) · 2024
    Trial
  18. Trial
  19. Review
  20. Article

229 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 2 institutions in 2 countries.

Emil Christensen1 Aarhus University Hospital, Aarhus, Denmark.
Karin Birkenkamp-Demtröder1 Aarhus University Hospital, Aarhus, Denmark.
Himanshu Sethi2 Natera, San Carlos, CA.
Svetlana Shchegrova2 Natera, San Carlos, CA.
Raheleh Salari2 Natera, San Carlos, CA.
Iver Nordentoft1 Aarhus University Hospital, Aarhus, Denmark.
Hsin-Ta Wu2 Natera, San Carlos, CA.
Michael Knudsen1 Aarhus University Hospital, Aarhus, Denmark.
Philippe Lamy1 Aarhus University Hospital, Aarhus, Denmark.
Sia Viborg Lindskrog1 Aarhus University Hospital, Aarhus, Denmark.
Ann Taber1 Aarhus University Hospital, Aarhus, Denmark.
Mustafa Balcioglu2 Natera, San Carlos, CA.
Søren Vang1 Aarhus University Hospital, Aarhus, Denmark.
Zoe Assaf2 Natera, San Carlos, CA.
Shruti Sharma2 Natera, San Carlos, CA.
Antony S Tin2 Natera, San Carlos, CA.
Ramya Srinivasan2 Natera, San Carlos, CA.
Dina Hafez2 Natera, San Carlos, CA.
Thomas Reinert1 Aarhus University Hospital, Aarhus, Denmark.
Samantha Navarro2 Natera, San Carlos, CA.
Alexander Olson2 Natera, San Carlos, CA.
Rosalyn Ram2 Natera, San Carlos, CA.
Scott Dashner2 Natera, San Carlos, CA.
Matthew Rabinowitz2 Natera, San Carlos, CA.
Paul Billings2 Natera, San Carlos, CA.
Styrmir Sigurjonsson2 Natera, San Carlos, CA.
Claus Lindbjerg Andersen1 Aarhus University Hospital, Aarhus, Denmark.
Ryan Swenerton2 Natera, San Carlos, CA.
Alexey Aleshin2 Natera, San Carlos, CA.
Bernhard Zimmermann2 Natera, San Carlos, CA.
Mads Agerbæk1 Aarhus University Hospital, Aarhus, Denmark.
Cheng-Ho Jimmy Lin2 Natera, San Carlos, CA.
Jørgen Bjerggaard Jensen1 Aarhus University Hospital, Aarhus, Denmark.
Lars Dyrskjøt1 Aarhus University Hospital, Aarhus, Denmark.
Natera (United States) · USAarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNovel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome for patients with bladder cancer. We addressed the prognostic and predictive impact of ultra-deep sequencing of cell-free DNA in patients before and after cystectomy and during chemotherapy. PATIENTS AND

methodsWe included 68 patients with localized advanced bladder cancer. Patient-specific somatic mutations, identified by whole-exome sequencing, were used to assess circulating tumor DNA (ctDNA) by ultra-deep sequencing (median, 105,000×) of plasma DNA. Plasma samples (n = 656) were procured at diagnosis, during chemotherapy, before cystectomy, and during surveillance. Expression profiling was performed for tumor subtype and immune signature analyses.

resultsPresence of ctDNA was highly prognostic at diagnosis before chemotherapy (hazard ratio, 29.1;

conclusionctDNA assessment for early risk stratification, therapy monitoring, and early relapse detection in bladder cancer is feasible and provides a basis for clinical studies that evaluate early therapeutic interventions.

Indexed as

Cell-Free Nucleic AcidsEarly Detection of CancerFemaleHumansLongitudinal StudiesMaleNeoplasm MetastasisNeoplasm Recurrence, LocalPrognosisRecurrenceUrinary Bladder NeoplasmsCell-Free Nucleic Acids

Identifiers

PMID31059311
OpenAlexW2944318130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.